Lundbeckfonden Ventures nyheder

SAN DIEGO, Sept. 21, 2017 /PRNewswire/ — Amplyx Pharmaceuticals, a biotechnology company developing novel antimicrobial agents for life-threatening fungal infections, today announced that seven posters from the APX001 development program will be presented at the Infectious Diseases Society of America (IDSA) IDWeek 2017, being held in San Diego, CA, from October 4 to 8, 2017. For the first time, the...
Presentation of multiple preclinical and clinical data from APX001 antifungal program SAN DIEGO – September 20, 2017 – Amplyx Pharmaceuticals, a biotechnology company developing novel antimicrobial agents for life-threatening fungal infections, today announced that seven posters from the APX001 development program will be presented at the Infectious Diseases Society of America (IDSA) IDWeek 2017, being...
BONESUPPORT APPOINTS JERRY CHANG AS EXECUTIVE VICE PRESIDENT OF RESEARCH & DEVELOPMENT Lund, Sweden, 12.00 CEST, 19 September 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces that it has appointed...
Lund, Sweden, 08.00 CEST, September 7th 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces that it has signed an Agency agreement with Novomedics to provide it with local support to...
Lund, Sweden, 31st August 2017 – During August, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of August 31, 2017, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 49,382,244. About BONESUPPORT® BONESUPPORT is an innovative and rapidly growing...
South San Francisco, CA – August 22, 2017 – Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced the appointment of Brandon Smith as Chief Operating Officer. He joins Iconic from Impax Laboratories, Inc., where he served as Senior Vice...
Lund, Sweden, 08.00 CEST, 17 August 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT™ platform today publishes its Interim Report, January-June 2017. FINANCIAL HIGHLIGHTS Q2 Net sales increased by 48% APRIL – JUNE...
Lund, Sweden, 11 August 2017 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery, will publish its Q2 2017 Interim Report on Thursday 17 August 2017 at 10am CEST. The Company will also host a conference call and an...
Company continuing the development of Nalbuphine® ER in chronic pruritus conditions New Haven, CT, July 20, 2017 – Trevi Therapeutics, Inc. (“Trevi” or the “Company”), announced today that the Company has completed a Series C financing of $50.5 million led by New Enterprise Associates (NEA). The financing round included new investors Lundbeckfonden Ventures, Omega Funds...
1 2 3 35